These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Nonfunctioning neuroendocrine tumors of the pancreas: clinical presentation of 7 patients. Closset J; Delhaye M; Sperduto N; Rickaert F; Gelin M Hepatogastroenterology; 1996; 43(12):1640-4. PubMed ID: 8975980 [TBL] [Abstract][Full Text] [Related]
10. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas. Bahra M; Jacob D; Pascher A; Plockinger U; Kristiansen G; Neuhaus P; Langrehr JM J Gastroenterol Hepatol; 2007 Jun; 22(6):930-5. PubMed ID: 17489964 [TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570 [TBL] [Abstract][Full Text] [Related]
12. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513 [TBL] [Abstract][Full Text] [Related]
13. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Klöppel G Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112 [TBL] [Abstract][Full Text] [Related]
14. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cho CS; Labow DM; Tang L; Klimstra DS; Loeffler AG; Leverson GE; Fong Y; Jarnagin WR; D'Angelica MI; Weber SM; Blumgart LH; Dematteo RP Cancer; 2008 Jul; 113(1):126-34. PubMed ID: 18457323 [TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345 [TBL] [Abstract][Full Text] [Related]
16. [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients]. Fendrich V; Habbe N; Celik I; Langer P; Zielke A; Bartsch DK; Rothmund M Dtsch Med Wochenschr; 2007 Feb; 132(5):195-200. PubMed ID: 17252361 [TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumors of pancreas: how can we apply the 2006 TNM proposal? Mboti FB; Loi P; Nagy N; Myriam D; Gelin M; Closset J Hepatogastroenterology; 2010; 57(98):344-8. PubMed ID: 20583440 [TBL] [Abstract][Full Text] [Related]
18. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Niederle MB; Hackl M; Kaserer K; Niederle B Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725 [TBL] [Abstract][Full Text] [Related]
19. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors. Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853 [TBL] [Abstract][Full Text] [Related]
20. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Casadei R; Ricci C; Rega D; D'Ambra M; Pezzilli R; Tomassetti P; Campana D; Nori F; Minni F Pancreas; 2010 Aug; 39(6):825-8. PubMed ID: 20431423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]